-
Sector Analysis
Plaque Psoriasis in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2030
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Plaque Psoriasis (PsO) market through 2030. GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady...
-
Sector Analysis
Plaque Psoriasis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030
This report covers the 7 major markets and provides an Excel-based forecast model for the Plaque Psoriasis market through 2030. GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady increase...
-
Product Insights
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Global Clinical Trials Review, 2025" provides an overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Clinical trials scenario. This report provides top line data relating to the clinical trials on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Sicca Syndrome (Sjogren) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025" provides an overview of Sicca Syndrome (Sjogren) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Myasthenia Gravis market through 2034. For the treatment of MG, most patients will be prescribed either corticosteroids or acetylcholinesterase inhibitors, with the corticosteroid prednisone and the acetylcholinesterase inhibitor pyridostigmine being the treatments most prescribed by physicians. When standard treatments fail, monoclonal antibodies are prescribed, offering more targeted, aggressive therapy. The MG market across the 7MM was valued at $6.1 billion in 2024 and is expected to grow...
-
Product Insights
Graft Versus Host Disease (GVHD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Graft Versus Host Disease (GVHD) - Global Clinical Trials Review, 2025" provides an overview of Graft Versus Host Disease (GVHD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Erythrodermic Psoriasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Erythrodermic Psoriasis - Global Clinical Trials Review, 2025" provides an overview of Erythrodermic Psoriasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Erythrodermic Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Diffuse Cutaneous Systemic Sclerosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diffuse Cutaneous Systemic Sclerosis - Global Clinical Trials Review, 2025" provides an overview of Diffuse Cutaneous Systemic Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Cutaneous Systemic Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Generalized Pustular Psoriasis (GPP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Generalized Pustular Psoriasis (GPP) Clinical Trial Report Overview A total of 67 Generalized Pustular Psoriasis (GPP) clinical trials were conducted as of August 2024. The GPP clinical trial report provides a comprehensive understanding of the GPP clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.